Disc Medicine, Inc. (IRON)
NASDAQ:IRON
Want to see IRON full AI Analyst Report?
Top Page
Disc Medicine
(NASDAQ:IRON)
Select Model
Select Model
Rating:47Neutral
Price Target:
$67.00
▼(-6.65% Downside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and heavy cash burn) and negative corporate events tied to the FDA Complete Response Letter and subsequent restructuring. Technicals are mixed/neutral and do not provide a strong offset, while valuation is difficult to support using P/E due to negative earnings and no dividend yield data.
Positive Factors
Balance-sheet liquidity
Sizable equity and very low leverage provide durable funding capacity to support multi-year clinical programs. This reduces immediate refinancing pressure, allowing management to prioritize trial completion and regulatory interactions without urgent capital raises that could overly dilute shareholders.
Negative Factors
Pre-revenue with widening losses
Being pre-revenue while losses and cash burn have materially increased creates persistent financing and dilution risk. Continued negative free cash flow means management must balance investment in clinical programs with the need to preserve capital, potentially forcing trade-offs or future equity raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet liquidity
Sizable equity and very low leverage provide durable funding capacity to support multi-year clinical programs. This reduces immediate refinancing pressure, allowing management to prioritize trial completion and regulatory interactions without urgent capital raises that could overly dilute shareholders.
Read all positive factors
Disc Medicine (IRON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.66B
Dividend YieldN/A
Average Volume (3M)438.31K
Price to Earnings (P/E)―
Beta (1Y)1.68
Revenue GrowthN/A
EPS Growth-68.57%
CountryUS
Employees94
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.64
Shares Outstanding38,199,090
10 Day Avg. Volume510,820
30 Day Avg. Volume438,315
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-15.46
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-15.04K
Enterprise Value/Ebitda-10.83
Forecast
1Y Price Target
$98.22Price Target Upside36.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-6.94
Revenue Forecast (FY)N/A
Disc Medicine Business Overview & Revenue Model
Company Description
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates tha...
How the Company Makes Money
Disc Medicine is a clinical-stage biopharmaceutical company and, based on publicly available information, does not have recurring commercial product revenue. Its funding and revenue, when present, are typically derived from (1) collaboration, lice...
Disc Medicine Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -176.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -244.32M | -207.94M | -108.27M | -76.23M | -47.39M | -30.90M |
| Net Income | -241.60M | -212.18M | -109.36M | -76.43M | -46.83M | -35.97M |
Balance Sheet | ||||||
| Total Assets | 750.21M | 806.88M | 496.77M | 368.00M | 200.21M | 92.41M |
| Cash, Cash Equivalents and Short-Term Investments | 730.16M | 791.15M | 489.88M | 360.38M | 194.61M | 88.04M |
| Total Debt | 31.06M | 1.86M | 30.00M | 2.10M | 1.33M | 7.06M |
| Total Liabilities | 61.78M | 67.05M | 53.19M | 22.88M | 23.61M | 156.61M |
| Stockholders Equity | 688.43M | 739.83M | 443.59M | 345.12M | 176.60M | -64.20M |
Cash Flow | ||||||
| Free Cash Flow | -201.34M | -181.33M | -94.43M | -73.55M | -42.40M | -27.60M |
| Operating Cash Flow | -201.25M | -180.39M | -93.93M | -73.46M | -42.25M | -27.53M |
| Investing Cash Flow | -63.36M | -394.30M | -292.33M | -89.00K | -151.00K | -68.00K |
| Financing Cash Flow | 230.85M | 473.41M | 218.31M | 239.38M | 148.98M | 89.93M |
Disc Medicine Technical Analysis
Positive
71.77
Price Trends
66.49
Positive
68.74
Positive
72.46
Negative
Market Momentum
0.40
Negative
59.78
Neutral
71.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRON, the sentiment is Positive. The current price of 71.77 is above the 20-day moving average (MA) of 67.87, above the 50-day MA of 66.49, and below the 200-day MA of 72.46, indicating a neutral trend. The MACD of 0.40 indicates Negative momentum. The RSI at 59.78 is Neutral, neither overbought nor oversold. The STOCH value of 71.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRON.
Disc Medicine Risk Analysis
Disc Medicine disclosed 83 risk factors in its most recent earnings report. Disc Medicine reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Disc Medicine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $2.65B | -1,167.33 | -1.41% | ― | 95.29% | 98.21% | |
62 Neutral | $4.44B | -204.82 | -26.79% | ― | 96.03% | 82.27% | |
58 Neutral | $2.58B | -52.99 | -14.19% | ― | 128.99% | 58.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.68B | -3.25 | -54.32% | ― | 11.07% | 32.35% | |
48 Neutral | $1.70B | -4.23 | -34.11% | ― | 78.34% | -161.91% | |
47 Neutral | $2.66B | -11.28 | -36.95% | ― | ― | -68.57% |
* Healthcare Sector Average
IRON
Disc Medicine
70.80
23.93
51.06%
AGIO
Agios Pharma
30.42
-1.42
-4.46%
TVTX
Travere Therapeutics
47.76
32.38
210.53%
ARQT
Arcutis Biotherapeutics
21.44
7.77
56.84%
TARS
Tarsus Pharmaceuticals
59.54
16.10
37.06%
RXRX
Recursion Pharmaceuticals
3.44
-1.01
-22.70%
Disc Medicine Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Disc Medicine Implements Restructuring Following FDA Response
Negative
Feb 27, 2026
On February 26, 2026, Disc Medicine, Inc.’s board approved a restructuring plan and management began implementation to better align its workforce with near-term strategic priorities after receiving a complete response letter from the U.S. Fo...
Business Operations and StrategyRegulatory Filings and Compliance
Disc Medicine Addresses FDA Rejection of Bitopertin Filing
Negative
Feb 17, 2026
Disc Medicine, Inc., a biopharmaceutical company developing therapies for hematologic diseases including rare conditions like erythropoietic protoporphyria, is advancing a pipeline led by bitopertin alongside other candidates such as DISC-0974 and...
Business Operations and StrategyRegulatory Filings and Compliance
Disc Medicine Receives FDA Complete Response on Bitopertin
Negative
Feb 13, 2026
Disc Medicine reported that on February 13, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter for its New Drug Application for bitopertin as a treatment for erythropoietic protoporphyria, halting its bid for accelerated...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.